Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) Shares Outstanding (Diluted Average) (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $45.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 3.44% to $45.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $45.2 million, a 3.44% increase, with the full-year FY2024 number at $43.9 million, up 23.04% from a year prior.
  • Shares Outstanding (Diluted Average) was $45.2 million for Q3 2025 at Werewolf Therapeutics, up from $45.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $45.2 million in Q3 2025 to a low of $1.2 million in Q1 2021.
  • A 5-year average of $33.0 million and a median of $35.2 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): skyrocketed 2128.89% in 2022, then grew 2.13% in 2025.
  • Werewolf Therapeutics' Shares Outstanding (Diluted Average) stood at $18.5 million in 2021, then skyrocketed by 56.4% to $28.9 million in 2022, then rose by 23.5% to $35.6 million in 2023, then increased by 23.04% to $43.9 million in 2024, then rose by 3.07% to $45.2 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Shares Outstanding (Diluted Average) are $45.2 million (Q3 2025), $45.0 million (Q2 2025), and $44.8 million (Q1 2025).